Azitra, Inc. AZTR
0.67 USD +0.08 (+14.23%)
At closeNov 13, 2026, 6:36 AM EST
0.65 -0.02 -2.77%
Pre-market · Nov 13, 6:36 AM ET
0.5613 Day range 0.6895
0.52 52-week range 3.91
- YTD
- -74.77%
- 1 year
- -83.49%
News
benzinga.com Anitra Q3 EPS $(0.29) Misses $(0.23) Estimate Anitra (AMEX:AZTR) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.23) by 31.82 percent. This is a 56.72 percent increase over losses of $(0.67) per…
prnewswire.com Azitra, Inc. Announces Q3 2026 Results and Provides Business Updates BRANFORD, Conn., Nov. 12, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies…- benzinga.com Azitra To Present Pipeline Updates Including Results For ATR-COSF Program, Designed To Deliver Filaggrin Domains Into Human Skin To Reduce Appearance Of Fine Lines And Wrinkles, At BIO-Europe Initial results from first-in-human study with ATR-COSF anticipated by year-endBRANFORD, Conn., Nov. 10, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE:AZTR), a clinical-stage
prnewswire.com Azitra, Inc. to Present Research at BIO-Europe® Showing ATR-COSF Reduced Fine Lines and Improved Elasticity in Ex Vivo Human Skin Models Initial results from first-in-human study with ATR-COSF anticipated by year-end BRANFORD, Conn., Nov. 10, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a…- benzinga.com Azitra Expands Eligibility For Ongoing Phase 1/2 Clinical Trial Of ATR04-484 To Include Individuals With Rash Associated With KRAS And MEK Inhibitors Expanded eligibility significantly broadens potential treatment opportunities for ATR-04 beyond EGFR inhibitor-associated skin rashAdditional protocol modifications expected to facilitate patient…
benzinga.com Why Celestica Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket Celestica jumps 16.4% after beating Q3 FY26 estimates and raising guidance; 22nd Century leads premarket gainers at 69.8%.
benzinga.com Azitra Suspends ATM Offering Program For The Foreseeable Future; From September 28, 2026 - October 26, 2026, The Company Sold An Aggregate Of 1,000 Shares Of Common Stock Under The ATM Program For Aggregate Gross Proceeds Of ~$126 ATM Program Effective October 26, 2026, the Company has decided not to utilize its at-the-market offering program (the "ATM Program") under the sales agreement, dated September 28, 2026, between the…
benzinga.com Azitra To Present Progress For Its Cosmetic ATR-COSF Program Targeting Fine Lines And Wrinkles At Bio-europe, November 10; First-In-Human Study With ATR-COSF Initial Results Anticipated By End Of 2026 ATR-COSF uses a supernatant based formulation containing an active recombinant human domain of the protein, filaggrin.Ex vivo data in two models of recent cosmetic surgery explants showed visible…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) stock moved upwards by 203.8% to $3.19 during Tuesday's regular session. The company's market cap stands at $2.6 million. Picard Medical (AMEX:PMI) stock…